Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

Company Looks At Coformulation

 
• By Alaric DeArment
Regeneron at ASCO • Source: Alaric DeArment

More from ASCO

More from Conferences